- Home
- IMUX vs RGLS Comparison
IMUX vs RGLS Comparison
Compare IMUX & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- RGLS
- Stock Information
- Founded
- IMUX 2016
- RGLS 2007
- Country
- IMUX United States
- RGLS United States
- Employees
- IMUX N/A
- RGLS N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- IMUX Health Care
- RGLS Health Care
- Exchange
- IMUX Nasdaq
- RGLS Nasdaq
- Market Cap
- IMUX 110.8M
- RGLS 102.1M
- IPO Year
- IMUX N/A
- RGLS 2012
- Fundamental
- Price
- IMUX $1.06
- RGLS $1.43
- Analyst Decision
- IMUX Strong Buy
- RGLS Strong Buy
- Analyst Count
- IMUX 5
- RGLS 6
- Target Price
- IMUX $13.20
- RGLS $10.33
- AVG Volume (30 Days)
- IMUX 1.5M
- RGLS 503.4K
- Earning Date
- IMUX 11-07-2024
- RGLS 11-07-2024
- Dividend Yield
- IMUX N/A
- RGLS N/A
- EPS Growth
- IMUX N/A
- RGLS N/A
- EPS
- IMUX N/A
- RGLS N/A
- Revenue
- IMUX N/A
- RGLS N/A
- Revenue This Year
- IMUX N/A
- RGLS N/A
- Revenue Next Year
- IMUX N/A
- RGLS N/A
- P/E Ratio
- IMUX N/A
- RGLS N/A
- Revenue Growth
- IMUX N/A
- RGLS N/A
- 52 Week Low
- IMUX $0.97
- RGLS $1.08
- 52 Week High
- IMUX $2.11
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- IMUX 28.31
- RGLS 44.08
- Support Level
- IMUX $1.15
- RGLS $1.38
- Resistance Level
- IMUX $1.28
- RGLS $1.65
- Average True Range (ATR)
- IMUX 0.08
- RGLS 0.11
- MACD
- IMUX -0.01
- RGLS 0.00
- Stochastic Oscillator
- IMUX 12.90
- RGLS 16.67
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.